
To conduct a systematic review and network meta‐analysis to determine the comparative effectiveness of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dipeptidyl peptidase‐4 (DPP‐4) inhibitors in patients with diabetic kidney disease (DKD). Sixteen trials representing a total of 46 292 patients were included. SGLT2 inhibitors significantly reduced the risk of the kidney‐specific composite outcome by 26% compared to GLP‐1RAs and 36% compared to DPP‐4 inhibitors. SGLT2 inhibitors demonstrated a clear advantage in reducing the risks of CV and renal events in patients with DKD compared to GLP‐1RAs and DPP‐4 inhibitors.
Like
Save
Share